Keywords: Ipsen, Financial results, First-half 2012
Ipsen posts 8% rise in first-half 2012 sales
Article | 28 August 2012
French drugmaker Ipsen (Euronext: IPN) yesterday reported first-half 2012 financial results with 8% growth in consolidated sales to 629.8 million euros ($788.3 million). Operating ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
